3 research outputs found
Molecular insights into the mechanisms of susceptibility of Labeo rohita against oomycete Aphanomyces invadans
No full textAphanomyces invadans, the causative agent of epizootic ulcerative syndrome, is one of the most destructive pathogens of freshwater fishes. To date, the disease has been reported from over 160 fish species in 20 countries and notably, this is the first non-salmonid disease that has resulted in major impacts globally. In particular, Indian major carps (IMCs) are highly susceptible to this disease. To increase our knowledge particularly with regards to host immune response against A. invadans infection in a susceptible host, the gene expression profile in head kidney of A. invadans-infected and control rohu, Labeo rohita was investigated using RNA sequencing. Time course analysis of RNA-Seq data revealed 5608 differentially expressed genes, involved among others in Antigen processing and presentation, Leukocyte transendothelial migration, IL-17 signaling, Chemokine signaling, C-type lectin receptor signaling and Toll-like receptor signaling pathways. In the affected pathways, a number of immune genes were found to be downregulated, suggesting an immune evasion strategy of A. invadans in establishing the infection. The information generated in this study offers first systematic mechanistic understanding of the host–pathogen interaction that might underpin the development of new management strategies for this economically devastating fish-pathogenic oomycete A. invadans.</p
Advances in the possible treatment of COVID-19: A review.
No full textThe emergence of the global pandemic caused by novel severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) has put a challenge to identify or derive the therapeutics for its prevention and treatment. Despite the
unprecedented advances in the modern medicinal system, currently, there are no proven effective therapies.
However, rapid research on SARS-CoV-2 epidemiology help unveiling some new targets for potential drug
therapies. Many drugs have been screened, and even their clinical trials are going on at an exceptional pace.
Amongst these RNA-dependent RNA polymerase inhibitors (favipiravir and remdesivir) and steroids especially
dexamethasone showed promising effects. The biological agents like tocilizumab, interferons, and convalescent
plasma prove to be beneficial in viral clearance. Moreover, many immunomodulatory and viral S protein targeting vaccines have their ongoing clinical trials. The establishment of various in vitro and in vivo models for
preclinical studies can additionally help the current research. The volume and the pace of the clinical trials
launched to evaluate the safety and efficacy of various agents against coronavirus disease 2019 (COVID-19)
reflect the need for high-quality evidence for various therapies to be practiced by clinicians. This study aims to
sum up all the current advances in the global medicinal system against the COVID-19
